75 related articles for article (PubMed ID: 36115256)
1. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
[TBL] [Abstract][Full Text] [Related]
2. Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.
Zhang S; Yao S; Chen J; Akter F; Yang J; Zhu D; Zeng A; Chen W; Mao Z; Zhu Y; Wang H
J Neurosurg; 2024 Apr; 140(4):1019-1028. PubMed ID: 37856412
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone tumor histological subtypes predict response to surgical and medical therapy.
Kiseljak-Vassiliades K; Carlson NE; Borges MT; Kleinschmidt-DeMasters BK; Lillehei KO; Kerr JM; Wierman ME
Endocrine; 2015 May; 49(1):231-41. PubMed ID: 25129651
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study.
Favero V; Zampetti B; Carioni EI; Dalino Ciaramella P; Grossrubatscher E; Dallabonzana D; Chiodini I; Cozzi R
Front Endocrinol (Lausanne); 2024; 15():1344728. PubMed ID: 38362280
[TBL] [Abstract][Full Text] [Related]
6. The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.
Dumitriu-Stan RI; Burcea IF; Nastase VN; Ceaușu RA; Dumitrascu A; Cocosila LC; Bastian A; Zurac S; Raica M; Poiana C
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003353
[TBL] [Abstract][Full Text] [Related]
7. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
Marques-Pamies M; Gil J; Valassi E; Hernández M; Biagetti B; Giménez-Palop O; Martínez S; Carrato C; Pons L; Villar-Taibo R; Araujo-Castro M; Blanco C; Simón I; Simó-Servat A; Xifra G; Vázquez F; Pavón I; García-Centeno R; Zavala R; Hanzu FA; Mora M; Aulinas A; Vilarrasa N; Librizzi S; Calatayud M; de Miguel P; Alvarez-Escola C; Picó A; Sampedro M; Salinas I; Fajardo-Montañana C; Cámara R; Bernabéu I; Jordà M; Webb SM; Marazuela M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1269787. PubMed ID: 38027102
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly.
Marques-Pamies M; Gil J; Jordà M; Puig-Domingo M
Arch Med Res; 2023 Dec; 54(8):102924. PubMed ID: 38042683
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature.
Kizilgul M; Duger H; Nasiroglu NI; Sencar E; Hepsen S; Akhanli P; Berker D; Cakal E; Bostan H; Ucan B
Arch Endocrinol Metab; 2022 May; 66(3):278-85. PubMed ID: 35612842
[TBL] [Abstract][Full Text] [Related]
11. Newer parameters of the octreotide test in patients with acromegaly.
Urai S; Yamamoto M; Yamamoto N; Suzuki M; Shichi H; Kanie K; Fujita Y; Bando H; Fukuoka H; Takahashi M; Iguchi G; Takahashi Y; Ogawa W
Pituitary; 2024 Feb; 27(1):33-43. PubMed ID: 37999819
[TBL] [Abstract][Full Text] [Related]
12. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly.
Clemmons DR; Bidlingmaier M
Front Endocrinol (Lausanne); 2023; 14():1266339. PubMed ID: 38027199
[TBL] [Abstract][Full Text] [Related]
13. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis.
Bonneville F; Rivière LD; Petersenn S; Bevan J; Houchard A; Sert C; Caron PJ;
Eur J Endocrinol; 2018 Dec; ():. PubMed ID: 30540560
[TBL] [Abstract][Full Text] [Related]
14. Preoperative and postoperative blood testosterone levels in patients with acromegaly: a prospective study.
Zhang D; Guo X; Feng M; Bao X; Deng K; Yao Y; Lian W; Xing B; Wang H
Front Endocrinol (Lausanne); 2023; 14():1259529. PubMed ID: 37886642
[TBL] [Abstract][Full Text] [Related]
15. Pathologic Characteristics of Somatotroph Pituitary Tumors-An Observational Single-Center Study.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137536
[TBL] [Abstract][Full Text] [Related]
16. Prolactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
Araujo-Castro M; Marazuela M; Puig-Domingo M; Biagetti B
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762304
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas.
Tang Y; Xie T; Guo Y; Liu S; Li C; Liu T; Zhao P; Yang L; Li Z; Yang H; Zhang X
World Neurosurg; 2024 Feb; 182():e334-e343. PubMed ID: 38052365
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors of cancers in acromegaly: a Chinese single-center retrospective study.
Xiao T; Jiao R; Yang S; Wang Y; Bai X; Zhou J; Li R; Wang L; Yang H; Yao Y; Deng K; Gong F; Pan H; Duan L; Zhu H
Endocrine; 2023 Nov; 82(2):368-378. PubMed ID: 37442901
[TBL] [Abstract][Full Text] [Related]
19. Predictors of biochemical response to somatostatin receptor ligands in acromegaly.
Marazuela M; Martínez-Hernandez R; Marques-Pamies M; Biagetti B; Araujo-Castro M; Puig-Domingo M
Best Pract Res Clin Endocrinol Metab; 2024 Mar; ():101893. PubMed ID: 38575404
[TBL] [Abstract][Full Text] [Related]
20. Acromegaly Type 1: A Representative Patient.
Cuevas-Ramos D; Melmed S
JCEM Case Rep; 2024 Apr; 2(4):luae053. PubMed ID: 38633358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
